Trials / Withdrawn
WithdrawnNCT02205788
Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas
Feasibility of Biodynamic Imaging for Predicting Effect of Gemcitabine and Nab-paclitaxel on Metastatic Adenocarcinoma of the Pancreas
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Patrick Joseph Loehrer Sr. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if you can use an assay on tumor samples to see different patterns in response to the same chemotherapy treatment.
Detailed description
To examine the feasibility of using biodynamic imaging (BDI) as a chemosensitivity assay on fresh tumor samples obtained by core needle biopsy from patients planned to receive routine care gemcitabine and nab-paclitaxel for treatment of metastatic adenocarcinoma of the pancreas.
Conditions
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-09-14
- Completion
- 2016-09-14
- First posted
- 2014-07-31
- Last updated
- 2019-07-10
Source: ClinicalTrials.gov record NCT02205788. Inclusion in this directory is not an endorsement.